08:00 , Nov 10, 2014 |  BC Week In Review  |  Clinical News

AMAP102: Phase IIa data

Top-line data from a double-blind Phase IIa trial in 116 patients with mild to moderate OA of the knee, either with or without hand OA, showed that AMAP102 missed the primary endpoint of reducing WOMAC...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Company News

Allenex, AnaMar deal

This month, Allenex will sell its 2.1% equity stake in AnaMar to AnaMar's main owner Koncentra Holding AB (Stockholm, Sweden) for SEK1.7 million ($256,581). Allenex became an owner in AnaMar in 1998. Allenex said it...
07:00 , Oct 6, 2011 |  BC Innovations  |  Cover Story

Opening the brain

A Cornell University team has proposed a new strategy for delivering large-molecule therapeutics into the CNS: agonizing adenosine receptors in the brain's vasculature to loosen up the blood brain barrier. 1 Private equity company KensaGroup...
07:00 , May 11, 2009 |  BioCentury  |  Finance

Ebb & Flow

What a difference a product approval makes. Activist investor Kevin Tang terminated his threatened proxy battle with Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) and withdrew his proposal to liquidate the company after FDA approved the biotech's Fanapt...
07:00 , May 4, 2009 |  BC Week In Review  |  Clinical News

AMAP102: Phase I started

AnaMar began a double-blind, placebo-controlled, single and multiple ascending-dose, U.K. Phase I trial to evaluate oral AMAP102 in 48 healthy volunteers. AnaMar Medical AB , Göteborg, Sweden   Product: AMAP102   Business: Autoimmune   Molecular...